Pfizer keeps declining, but it is not the only pandemic player to suffer.
Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.
Imjudo’s clinical development period was almost the longest of any drug in recent memory. Here are some others.
M&A is back on the menu, but there are still reasons to be cautious.
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
The group is taking a subcutaneous formulation of efgartigimod to regulators, but is keeping quiet about price.